Long-term therapy with Eribulin in a patient with heavily-pretreated metastatic breast cancer – a case report

Introduction: We report the case of a 60-year-old woman with metastatic breast cancer treated with Eribulin as sixth-line chemotherapy. Currently, she receives the 34th-cycle of Eribulin without any significant side-effects and with the enormous benefit of a stable disease for two years. Methods: A retrospective review of clinical and treatment data of our patient since the start of Eribulin treatment. Results: We Chose as sixth-line chemotherapy we chose Eribulin and began with the first cycle on April 23rd 2012. She receives 1.23 mg/m2 Eribulin at day 1 and day 8 repeated every 21 days. Eribulin is injected as…